When former President Trump came down with COVID-19, one of the treatments his doctors used was the Regeneron antibody infusion. He attributed his rapid recovery to this monoclonal medicine, which is a combination of casirivimab and imdevimab. It was developed specifically to block infection with the SARS-CoV-2 virus that causes COVID-19.
Clinical Trial Shows Benefits from Regeneron Antibody Infusion:
This treatment is designed not to prevent COVID-19 like the vaccines, but rather to help people recover before they need hospital care. Regeneron has just completed a phase 3 randomized controlled trial of this therapy. One percent of the patients who received a low dose of the monoclonal antibodies required hospitalization. In comparison, more than 3 percent of those who got placebo infusions landed in the hospital.
In its press release, the company reports this as a 70% relative risk reduction. The absolute risk, on the other hand, dropped by approximately 2%. At the higher dose, there was a bigger spread: 1.3% of volunteers were hospitalized or died if they received the treatment. In contrast, 4.6% of those who received placebo had bad outcomes. The results of the study have not yet been published in a peer-reviewed journal.
